Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	356.64M
Revenue (ttm)	143.68M
Net Income (ttm)	-68.20M
Shares Out	27.12M
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	529,441
Open	13.31
Previous Close	13.31
Day's Range	12.77 - 13.51
52-Week Range	8.04 - 25.88
Beta	2.27
Analysts	Strong Buy
Price Target	52.83 (+301.75%)
Earnings Date	Aug 4, 2025

About ARCT

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOS...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 176
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT
• Website: https://arcturusrx.com

Financial Performance

In 2024, ARCT's revenue was $152.31 million, a decrease of -8.69% compared to the previous year's $166.80 million. Losses were -$80.94 million, 172.3% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for ARCT stock is "Strong Buy." The 12-month stock price target is $52.83, which is an increase of 301.75% from the latest price.

Price Target

$52.83

(301.75% upside)

Analyst Consensus: Strong Buy